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Abstract From very recent studies, including molecular cloning 
of cDNA coding for membrane receptors, lysophosphatidic acid 
(LPA) reached the status of a novel phospholipid mediator with 
various biological activities. Another strong argument supporting 
this view was the discovery that LPA is secreted from activated 
platelets, resulting in its appearance in serum upon blood 
coagulation. The metabolic pathways as well as the enzymes 
responsible for LPA production are poorly characterized. 
However, a survey of literature data indicates some interesting 
issues which might be used as the basis for further molecular 
characterization of phospholipases A able to degrade phospha-
tidic acid. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Lysophosphatidic acid (LPA) is the simplest phospholipid 
found in nature and for a while was considered only as the 
transient first intermediate in the de novo synthesis of glycer-
ophospholipids [1]. However, a number of studies starting in 
the 1960s described several biological activities displayed by 
LPA, including smooth muscle contraction [2], vasoactive ef-
fects [3] or platelet aggregation [4-6]. However, especially 
when considering platelet aggregation, LPA still appeared as 
a poor effector compared to the unique phospholipid media-
tor described so far, i.e. platelet activating factor or 1-O-alkyl-
2-acetyl-,s«-glycero-3-phosphocholine [7]. More recently, Moo-
lenaar and colleagues in Amsterdam observed that LPA pos-
sesses all the properties of an authentic growth factor [8]. This 
stimulated a renewed interest for LPA, which now appears to 
be a widespread mediator active not only on mammalian cells 
but also on more ancestral cells such as Xenopus laevis oocytes 
or Dictyostelium dicoideum. At the present time, an impressive 
number of biological activities have been described and in-
clude, in addition to properties mentioned above, stimulation 
of chemotaxis, of tumour invasion, dedifferentiating effects on 
neuronal cells in culture, antiproliferative effects (depending 
on cell type and concentration), cytoskeletal rearrangement, 
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calcium mobilization as well as modulation of chloride chan-
nels. All these data have been recently compiled in a number 
of excellent reviews [9-15]. 
Confirming previous predictions based on the study of sig-
nal transduction mechanisms, two cDNA encoding putative 
LPA receptors have recently been cloned, indicating that the 
phospholipid acts via G-protein-coupled receptors displaying 
the characteristic features of seven transmembrane proteins 
[16-18]. This provided definitive evidence for LPA being an 
extracellular mediator, a concept which has only recently 
emerged from the observation that it is present in serum at 
micromolar concentrations and might be secreted by platelets 
[19,20]. Based on its effects on fibroblast proliferation, this has 
led to the suggestion that LPA might be involved in wound 
healing [9-15]. However, platelets might not be the only 
source of LPA. The aim of this short review is to focus on 
the available information dealing with LPA biosynthesis. 
2. Role of platelets in LPA biosynthesis 
By incubating platelets with phospholipase C (PLC) from 
Clostridium welchii, we obtained the first evidence that these 
cells are able to synthesize LPA, as shown by 32P labelling 
(Fig. 1) [21]. The same was observed with thrombin, although 
at a much lower rate, probably because diacylglycerol (DAG) 
generated from phosphoinositides by endogenous PLC was 
much less abundant than DAG derived from hydrolysis of 
phosphatidylcholine by the bacterial enzyme. In both cases, 
it was evident that DAG was converted into phosphatidic acid 
by platelet DAG kinase. As illustrated in Fig. 2, one obvious 
possibility to generate LPA under these conditions would 
have been the hydrolysis of PA by a phospholipase A2 
(PLA2). However, LPA formed in thrombin-stimulated plate-
lets contains arachidonic acid, together with palmitic and ste-
aric acids, suggesting the possible involvement of a phospho-
lipase Aj (PLAj) [22]. In platelets treated with C. welchii PLC, 
the fatty acid composition of LPA is very similar to that of 
fatty acids occupying the sn-2 position of platelet phospha-
tidylcholine [21]. However, we were unable to detect any PLA 
activity in human platelet lysates, whereas PLA! and PLA2 
activities specific for PA were described in pig and horse pla-
telets, respectively [23,24]. Such a discrepancy might be due to 
species differences or to conditions of incubation. In any case, 
this led us to suggest that DAG could be deacylated by a 
specific lipase, the intermediate monoacylglycerol (MAG) 
being either further deacylated or phosphorylated into LPA, 
as illustrated in Fig. 2. This was based on the identification in 
platelet lysates of a DAG lipase activity [21], which was later 
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separated into a DAG and a MAG lipase [25,26]. At that 
time, a major interest arose as to the mechanisms of arach-
idonic acid release so that we and others suggested that this 
was the main role of platelet DAG lipase [21,27]. Since none 
of these enzymes has been isolated so far, it is still difficult to 
conclude how LPA is synthesized in activated platelets. More-
over, although phospholipase D seems to play a minor role 
in the production of platelet PA [28,29], its possible con-
tribution to the metabolic pathway leading to LPA would 
deserve further consideration. This hypothesis is also indi-
cated in Fig. 2. 
As stated above, a main advance in the field of LPA was 
the demonstration of its release from platelets [20]. Since it 
was identified in serum but not in plasma, an obvious con-
clusion was that platelets represented the main source of LPA 
formed during blood coagulation [19,20]. This point deserves 
some discussion, based on quantitative data. 
3. Are platelets the only source of LPA present in serum? 
As shown in Table 1, the amounts of LPA synthesized by 
PLC-treated platelets reached 26 nmol/109 platelets within 15 
min [21]. Starting from these data, it was possible to convert 
LPA radioactivity determined under other conditions into 
mass estimations. The value of 36 nmol/109 platelets upon 
incubation with PLC for 30 min could be considered as the 
maximal capacity of platelets to synthesize LPA. In vivo, this 
would result into a final concentration of LPA in serum of 
almost 20 uM. In contrast, when thrombin is used as a stimu-
lant, the expected final concentration of serum LPA would be 
0.6-0.9 |J,M when taking into account data from [20,21]. The 
latter values are higher than the mass determination made by 
Gerrard and Robinson [22] using gas-liquid chromatography. 
However, one can notice that the shorter incubation time used 
by these authors (2 min vs. 10-15 min) also resulted into a 
poorer labelling of LPA (Table 1). Thus, we think that the 
values of 0.6-0.9 |J,M extrapolated from radioactivity determi-
nation would better fit with the reality. These numbers are in 
the same range as those determined in serum by phosphorus 
measurement (1-5 |xM) [20], although they appear signifi-
cantly lower. In fact, LPA concentrations attaining 28 (J.M 
were reported in fetal calf serum [30]. This comparison leads 
to additional suggestions, which might be the basis of further 
investigations: either other blood cells (neutrophils, mono-
cytes, ...) contribute to the production of LPA or thrombin 
stimulation of platelets does not reflect exactly what occurs in 
vivo. 
At the same time, one should keep in mind that rat plasma 
contains a lysophospholipase D responsible for the accumu-
lation of LPA upon prolonged incubation [31]. According to 
the latter study, plasma concentrations of LPA as high as 66 
uM can be obtained after 48 h incubations. Whether this still 
poorly characterized enzyme is activated during coagulation 
should also be checked before reaching a definitive conclu-
sion. 
Finally, Tokumura et al. [31] found that plasma lysophos-
pholipase D can also degrade the lyso derivative of platelet 
activating factor, allowing the formation of alkyl-lysophos-
phatidic acid. Since this analogue shares some biological 
properties with LPA and is even 30-fold more active towards 
platelets [7,32,33], this possible metabolic pathway should not 
be neglected. 
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Fig. 1. Production of 32P-labelled LPA and PA in human platelets 
stimulated with PLC or thrombin. Human platelets were incubated 
with [32P]o-phosphate, washed and incubated for the indicated times 
with either C. welchii PLC (0.1 IU/ml) or thrombin (THR, 5 NIH 
U/ml). Lipids were then extracted, separated by thin-layer chroma-
tography and determined for radioactivity. Data are from Figs. 1 
and 2 in [21]. 
4. Loss of membrane phospholipid asymmetry regulating 
phosphatidic acid hydrolysis by secretory non-pancreatic 
phospholipase A2 
In a more recent study, we have focused our attention on 
the possible involvement of secretory non-pancreatic PLA2 
(snpPLA2 or type II PLA2) in the generation of lipid media-
tors like LPA [34]. This enzyme is produced by a number of 
cells stimulated by pro-inflammatory cytokines such as inter-
leukin-l(3 or tumor necrosis factor-a and it accumulates in 
inflammatory fluids as well as in the plasma of patients suffer-
ing from septic shock [35-37]. In these situations, the amounts 
of snpPLA2 secreted in these extracellular media reflect the 
severity of the inflammatory reaction [35-37]. A classical view 
is to consider that snpPLA2 might be involved as a distal 
effector of inflammation participating in the release of arach-
idonic acid or lysophospholipids, thus allowing the synthesis 
of various lipid mediators [36]. A difficulty with snpPLA2 is to 
understand how it could participate in this process as an ex-
tracellular enzyme, owing to its failure to degrade phospho-
lipids of intact cells. We provided evidence that snpPLA2 
acquires the ability to hydrolyse its substrates in cell mem-
branes after loss of phospholipid asymmetry [34]. Indeed, type 
II PLA2 remains almost inactive against choline-containing 
phospholipids forming the external layer of plasma mem-
branes but hydrolyses much more efficiently the aminophos-
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Fig. 2. Possible pathways of LPA production in activated platelets. Abbreviations not defined in the text are: PIP2, phosphatidylinositol(4,5)W.s-
phosphate; PC, phosphatidylcholine; PLD, phospholipase D. 
pholipids confined to the inner leaflet of cell membranes. Such 
a behaviour was demonstrated using microvesicles shed from 
red cells treated with a calcium ionophore, which have been 
shown to expose on their surface phosphatidylethanolamine 
and phosphatidylserine translocated from the internal leaflet. 
This model actually reflects what occurs under physiological 
and pathophysiological conditions such as platelet activation 
with thrombin plus collagen [38], cell damage with perforins 
[39,40], or apoptosis [41]. 
When microvesicles are released from calcium-loaded eryth-
rocytes, phosphoinositide-specific PLC is activated [42]. This 
is followed by accumulation of PA, which is redistributed 
between the tow leaflets of the membrane, part of it becoming 
accessible to snpPLA2 attack. LPA generated under these 
conditions can be bound to serum albumin and was shown 
to display the same biological properties as LPA [34]. 
This study thus unravelled a novel possible pathway for 
LPA synthesis. Studies are still in progress to define patho-
physiological conditions where activated cells would associate 
accumulation of PA in their membrane with profound 
changes of phospholipid transverse distribution. Although 
some possibilities exist, particularly in the field of inflamma-
tion, evidence is still lacking that LPA accumulates in inflam-
matory fluids. However, this study opens the view that the 
generation of LPA on the outer surface of cell membranes 
might represent a key event allowing its availability to albu-
min and secondarily to target cells. Although we did not yet 
obtain definitive proof for this, it is our conviction that only 
extracellularly generated LPA could become a mediator, 
whereas intracellular LPA would remain sequestered by fatty 
acid binding protein [43^15]. But this is only a speculative 
view, and one should also remember that other lipid media-
tors are synthesized intracellularly, for instance in nuclear or 
endoplasmic reticulum membrane [46^18], and are secreted to 
the surrounding medium by a still undefined mechanism [49]. 
In any case, snpPLA2 was the first reported example of a 
well-characterized phospholipase able to generate LPA di-
rectly from PA. There are presently an increasing number of 
Table 1 
Estimation of the amounts of LPA produced by platelets 
Conditions of stimulation 
PLC (15 min) 
PLC (30 min) 
Thrombin (15 min) 
Thrombin (10 min) 
Thrombin (2 min) 
Radioactivity8 
(arbitrary units) 
50 
70 
3.0 
1.9 
0.13 
Mass 
(nmol/109 
26 
36b 
1.6b 
1.0b 
0.014 
platelets) 
Expected serum concentration0 
(uM) 
14 
19.6 
0.9 
0.6 
0.008 
Ref. 
[21] 
[21] 
[21] 
[20] 
[22] 
"Arbitrary units are defined as the ratio between LPA radioactivity in stimulated platelets and PA radioactivity in resting platelets. 
bThese are values extrapolated from the comparison between radioactivity and mass determination of LPA in platelets treated for 15 min with 
PLC. 
Calculated with a platelet concentration of 3 X109 cells/ml and an haematocrit of 45%. 
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purified phospholipases A displaying either an absolute spe-
cificity or a high selectivity for PA. These are discussed below. 
5. Calcium-independent phospholipases A displaying selectivity 
for phosphatidic acid 
Thomson and Clark [50] recently purified from rat brain a 
58-kDa PLA2 absolutely specific for PA and acting in the 
absence of calcium. This enzyme would certainly deserve fur-
ther characterization, including a precise cellular and subcel-
lular localization, since LPA receptors appear to be rather 
abundant in cerebral tissue [16,18]. Bovine brain also contains 
a PA-preferring PLA l5 which is expressed in testis as well [51]. 
The purified enzyme appears to be a homotetramer of 110-
kDa subunits. A similar tetrameric structure has been ob-
served for a calcium-independent PLA2 whose cDNA was 
recently cloned and which displays a 20-fold preference for 
PA compared to phosphatidylcholine [52-54]. Of course, 
none of these enzymes can yet be considered as a direct effec-
tor of LPA production, but their molecular characterization 
could lead to interesting conclusions in a near future, allowing 
for instance to manipulate cells by transfection of cDNA cod-
ing for active or inactive enzymes. 
6. Conclusions 
At the end of this short review, we are far from providing a 
clear picture of the main metabolic pathway(s) responsible for 
LPA generation. Even in platelets, a rather high number of 
possibilities (and uncertainties) still exist and will probably be 
clarified in a near future. However, platelets are certainly not 
the only source of LPA, which has been found for instance at 
relatively high concentrations in normal follicular [55] and 
pathological cerebrospinal fluids [56]. Very surprisingly, 
LPA has been also detected in various tissues from rat and 
guinea pig at levels comprised between 50 and 140 nmol/g 
[57]. In these cases, it was found highly enriched in stearic 
acid, suggesting another source than phospholipid de novo 
synthesis. This kind of investigation might appear obsolete 
now that a great deal of effort will be devoted to the func-
tional and structural characterization of recently cloned LPA 
receptors [15-17]. We are convinced that the metabolic path-
ways of LPA biosynthesis are of prime importance for a bet-
ter biological definition of this novel mediator. They might 
also offer some clues to find pharmacological compounds 
able to modulate not only the activity but also the availability 
of LPA. 
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